Document:

Exhibit 4.5

 

	
        NUMBER

        ________
	 	
        (SEE REVERSE SIDE FOR LEGEND) 

        THIS WARRANT WILL BE VOID IF NOT 

        EXERCISED PRIOR TO THE EXPIRATION 

        OF THE EXERCISE PERIOD PROVIDED FOR

        IN THE WARRANT AGREEMENT DESCRIBED BELOW
	 	  WARRANTS

 

LONGEVITY
ACQUISITION CORPORATION

 

WARRANT

 

THIS CERTIFIES THAT, for
value received  

 

is
the registered holder of a warrant or warrants (the “Warrant”), expiring at 5:00 p.m., New York City time, on the five
year anniversary of the completion by Longevity Acquisition Corporation, a British Virgin Islands company (the “Company”),
of an acquisition, share exchange, share reconstruction and amalgamation, contractual control arrangement or other similar business
combination with one or more businesses or entities (a “Business Combination”), to purchase one half (1/2) of one fully
paid and non-assessable ordinary share, no par value (“Shares”), of the Company for each Warrant evidenced by this
Warrant Certificate.  The Warrant entitles the holder thereof to purchase from the Company, commencing on the later of
(a) one year from the date of the final prospectus relating to the Company’s initial public offering and (b) the Company’s
completion of a Business Combination, such whole number of Shares of the Company at the price of $11.50 per whole share, upon surrender
of this Warrant Certificate and payment of the Warrant Price at the office or agency of the Warrant Agent, Continental Stock Transfer
 & Trust Company, but only subject to the conditions set forth herein and in the Warrant Agreement between the Company and Continental
Stock Transfer & Trust Company, as Warrant Agent.  In no event will the Company be required to net cash settle any
warrant exercise. The Warrant Agreement provides that upon the occurrence of certain events the Warrant Price and the number of
Shares purchasable hereunder, set forth on the face hereof, may, subject to certain conditions, be adjusted.  The term
Warrant Price as used in this Warrant Certificate refers to the price per Share at which Shares may be purchased at the time the
Warrant is exercised. Defined terms used in this Warrant Certificate but not defined herein shall have the meanings given to them
in the Warrant Agreement.

 

No
fraction of a Share will be issued upon any exercise of a Warrant.  A warrantholder may exercise its warrants only for
a whole number of shares.  This means that only an even number of warrants may be exercised at any given time by a warrantholder.

 

Upon
any exercise of the Warrant for less than the total number of full Shares provided for herein, there shall be issued to the registered
holder hereof or the registered holder’s assignee a new Warrant Certificate covering the number of Shares for which the Warrant
has not been exercised.

 

Warrant
Certificates, when surrendered at the office or agency of the Warrant Agent by the registered holder hereof in person or by attorney
duly authorized in writing, may be exchanged in the manner and subject to the limitations provided in the Warrant Agreement, but
without payment of any service charge, for another Warrant Certificate or Warrant Certificates of like tenor and evidencing in
the aggregate a like number of Warrants.

 

    	 

     

    

 

Upon
due presentment for registration of transfer of the Warrant Certificate at the office or agency of the Warrant Agent, a new Warrant
Certificate or Warrant Certificates of like tenor and evidencing in the aggregate a like number of Warrants shall be issued to
the transferee in exchange for this Warrant Certificate, subject to the limitations provided in the Warrant Agreement, without
charge except for any applicable tax or other governmental charge.

 

The
Company and the Warrant Agent may deem and treat the registered holder as the absolute owner of this Warrant Certificate (notwithstanding
any notation of ownership or other writing hereon made by anyone), for the purpose of any exercise hereof, of any distribution
to the registered holder, and for all other purposes, and neither the Company nor the Warrant Agent shall be affected by any notice
to the contrary.

 

This
Warrant does not entitle the registered holder to any of the rights of a shareholder of the Company. This Warrant Certificate shall
be governed by and construed in accordance with the internal laws of the State of New York.

  

The
Company reserves the right to redeem the Warrant at any time prior to its exercise with a notice of redemption in writing to the
holders of record of the Warrant, giving at least 30 days’ notice of such redemption, at any time while the Warrant is exercisable,
if the last sale price of the Shares has been at least $16.50 per share (as adjusted for stock splits, stock dividends, reorganizations
and recapitalizations) on each of 20 trading days within any 30 trading day period (the “30-day trading period”) ending
on the third trading day prior to the date on which notice of such call is given and if, and only if, there is a current registration
statement in effect with respect to the Shares underlying the Warrants for each day of the 30-day trading period and continuing
each day thereafter until the date of redemption.  The redemption price of the Warrants is to be $0.01 per Warrant.  Any
Warrant either not exercised or tendered back to the Company by the end of the date specified in the notice of call shall be canceled
on the books of the Company and have no further value except for the $0.01 call price.

 

	By	 	 	 
	 	 	SEAL	 
	 	Chief Executive Officer	2018	Chief Executive Officer

 

    	 

     

    

 

ELECTION
TO PURCHASE

To
Be Executed by the Registered Holder in Order to Exercise Warrants

 

The
undersigned Registered Holder irrevocably elects to exercise ______________ Warrants represented by this Warrant Certificate,
and to purchase the ordinary shares issuable upon the exercise of such Warrants, and requests that Certificates for such shares
shall be issued in the name of

 

	(PLEASE TYPE OR PRINT NAME AND ADDRESS)
	 
	 

(SOCIAL
SECURITY OR TAX IDENTIFICATION NUMBER)

 

and be delivered to                                                  

(PLEASE
PRINT OR TYPE NAME AND ADDRESS)

 

and,
if such number of Warrants shall not be all the Warrants evidenced by this Warrant Certificate, that a new Warrant Certificate
for the balance of such Warrants be registered in the name of, and delivered to, the Registered Holder at the address stated below:

 

	Dated:	 	 	 
	 	 	 	(SIGNATURE)
	 	 	 	 
	 	 	 	(ADDRESS)
	 	 	 	 
	 	 	 	 
	 	 	 	(TAX IDENTIFICATION NUMBER)

  

THE SIGNATURE MUST BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION
(BANKS, STOCKBROKERS, SAVINGS AND LOAN ASSOCIATIONS AND CREDIT UNIONS WITH MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE MEDALLION
PROGRAM, PURSUANT TO S.E.C. RULE 17Ad-15 UNDER THE SECURITIES ACT OF 1933, AS AMENDED).

  

    	 

     

    

 

ASSIGNMENT

To
Be Executed by the Registered Holder in Order to Assign Warrants

 

For Value Received, _______________________
hereby sell, assign, and transfer unto

 

	(PLEASE TYPE OR PRINT NAME AND ADDRESS)
	 
	 

(SOCIAL
SECURITY OR TAX IDENTIFICATION NUMBER)

 

and be delivered to                                               

(PLEASE
PRINT OR TYPE NAME AND ADDRESS)

 

______________________
of the Warrants represented by this Warrant Certificate, and hereby irrevocably constitute and appoint _________________________________
Attorney to transfer this Warrant Certificate on the books of the Company, with full power of substitution in the premises.

  

	Dated:	 	 	 
	 	 	 	(SIGNATURE)

 

THE
SIGNATURE TO THE ASSIGNMENT FORM MUST BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION (BANKS, STOCKBROKERS, SAVINGS AND LOAN
ASSOCIATIONS AND CREDIT UNIONS WITH MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM, PURSUANT TO S.E.C. RULE 17Ad-15
UNDER THE SECURITIES ACT OF 1933, AS AMENDED).Exhibit 10.9

 

 

	 	9 Bond Court
	 	Leeds
	 	LS1 2JZ
	 	 
	 	Tel: 0113 895 0130
	 	 
	 	www.4Dpharmaplc.com

 

Private & Confidential

Katrin Rupalla

Gartengasse 12

CH- 4125 Riehen

 

18 August 2020

 

Dear Katrin

 

Letter of appointment

 

The board of directors (Board) of
4D pharma plc (Company) has appointed you as non-executive director. This letter sets out the terms of your appointment.
If you are unhappy with any of the terms, or need any more information, please let me know.

 

By accepting this appointment, you agree
that this letter is a contract for services and is not a contract of employment and you confirm that you are not subject to any
restrictions which prevent you from holding office as a director of the Company.

 

		1	Appointment

 

		1.1	Subject to the remaining provisions of this letter, your appointment shall continue unless terminated
by either party giving to the other three months’ prior written notice.

 

		1.2	Your appointment is subject to the Company’s articles of association, as amended from time
to time (Articles). Nothing in this letter shall be taken to exclude or vary the terms of the Articles as they apply to
you as a director of the Company. The Articles require any director appointed by the board to retire and seek re-election by the
shareholders at the Company’s annual general meeting (AGM) and, thereafter, generally one third of the directors to
retire by rotation and seek re-election at each AGM.

 

		1.3	Continuation of your appointment is contingent on your continued satisfactory performance and re-election
by the shareholders and any relevant statutory provisions relating to removal of a director. If the shareholders do not re-elect
you as a director, or you are retired from office under the Articles, your appointment shall terminate automatically, with immediate
effect and without compensation beyond termination.

 

Registered Office: 4D pharma plc 9 Bond
Court Leeds LS1 2JZ United Kingdom

Registered In England and Wales, Company Number 08840579

 

     

     

    

 

		1.4	You may be required to serve on one or more Board committees. You will be provided with the relevant
terms of reference on your appointment to such a committee.

 

		1.5	Notwithstanding paragraphs 1.1 to 1.4 (inclusive), the Company may terminate your appointment with
immediate effect if you have:

 

		1.5.1	committed a material breach of your obligations under this letter;

 

		1.5.2	committed any serious or repeated breach or non-observance of your obligations to the Company (which
include an obligation not to breach your statutory, fiduciary or common law duties);

 

		1.5.3	been guilty of any fraud or dishonesty or acted in any manner which, in the Company’s opinion,
brings or is likely to bring you or the Company into disrepute, or is materially adverse to the Company’s interests;

 

		1.5.4	been convicted of an arrestable criminal offence other than a road traffic offence for which a
fine or non-custodial penalty is imposed;

 

		1.5.5	been declared bankrupt or have made an arrangement with or for the benefit of your creditors; or

 

		1.5.6	been disqualified from acting as a director.

 

 

		1.6	On termination of your appointment you shall, at the Company’s request, resign from your
office as director of the Company and any offices you hold in any of the Company’s group companies.

 

		1.7	If matters arise which cause you concern about your role, you should discuss these matters with
the chairman. If you have any concerns which cannot be resolved, and you choose to resign for that, or any other, reason, you should
provide an appropriate written statement to the chairman for circulation to the Board.

 

		2	Time Commitment

 

		2.1	You will be expected to devote such time as is necessary for the proper performance of your duties.
This will include attendance at bi-monthly (i.e. every second month) Board meetings and the AGM, meetings with the non-executive
directors, meetings with shareholders, meetings forming part of the Board evaluation process, and updating and training meetings.
In addition, you will be required to consider all relevant papers before each meeting. Unless urgent and unavoidable circumstances
prevent you from doing so, it is expected that you will attend the meetings outlined in this paragraph.

 

		2.2	The nature of the role makes it impossible to be specific about the maximum time commitment. You
may be required to devote additional time to the Company in respect of preparation time and ad hoc matters which may arise, particularly
when the Company is undergoing a period of increased activity. At certain times it may be necessary to convene additional Board,
committee or shareholder meetings.

 

		2.3	By accepting this appointment you confirm that, taking into account all of your other commitments,
you are able to allocate sufficient time to the Company to discharge your responsibilities effectively.

 

    2 

     

    

 

		3	Role and Duties

 

		3.1	The Board as a whole is collectively responsible for the success of the Company. The Board’s
role is to:

 

		3.1.1	provide entrepreneurial leadership of the Company within a framework of prudent and effective controls
which enable risk to be assessed and managed;

 

		3.1.2	set the Company’s strategic aims, ensure that the necessary financial and human resources
are in place for the Company to meet its objectives, and review management performance; and

 

		3.1.3	set the Company’s values and standards and ensure that its obligations to its shareholders
and others are understood and met.

 

		3.2	As a non-executive director you shall have the same general legal responsibilities to the Company
as any other director. You are expected to perform your duties (whether statutory, fiduciary or common law) faithfully, diligently
and to a standard commensurate with the functions of your role and your knowledge, skills and experience.

 

		3.3	You shall exercise your powers in your role as a non-executive director having regard to relevant
obligations under prevailing law and regulation, including the Companies Act 2006 and the AIM Rules for Companies relating to the
AIM market operated by the London Stock Exchange.

 

		3.4	You shall have particular regard to the general duties of directors in Part 10, Chapter 2 of the
Companies Act 2006, including the duty to promote the success of the Company under which all directors must act in the way they
consider, in good faith, would be most likely to promote the success of the Company for the benefit of its members as a whole.
In doing so, as a director, you must have regard (among other matters) to:

 

		3.4.1	the likely consequences of any decision in the long term;

 

		3.4.2	the interests of the Company’s employees;

 

		3.4.3	the need to foster the Company’s business relationships with suppliers, customers and others;

 

		3.4.4	the impact of the Company’s operations on the community and the environment;

 

		3.4.5	the desirability of the Company maintaining a reputation for high standards of business conduct;
and

 

		3.4.6	the need to act fairly as between the members of the Company.

 

		3.5	In your role as a non-executive director, you shall also be required to:

 

		3.5.1	constructively challenge and help develop proposals on strategy;

 

		3.5.2	scrutinise the performance of management in meeting agreed goals and objectives, and monitor the
reporting of performance;

 

    3 

     

    

 

		3.5.3	satisfy yourself on the integrity of financial information and that financial controls and systems
of risk management are robust and defensible;

 

		3.5.4	be responsible for determining appropriate levels of remuneration of executive directors and have
a prime role in appointing and, where necessary, removing senior management and in succession planning;

 

		3.5.5	devote time to developing and refreshing your knowledge and skills;

 

		3.5.6	uphold high standards of integrity and probity and support the executive directors in instilling
the appropriate culture, values and behaviours in the boardroom and beyond;

 

		3.5.7	insist on receiving high-quality information sufficiently in advance of Board meetings;

 

		3.5.8	take into account the views of shareholders and other stakeholders where appropriate;

 

		3.5.9	make sufficient time available to discharge your responsibilities effectively;

 

		3.5.10	exercise relevant powers under, and abide by, the Articles;

 

		3.5.11	disclose the nature and extent of any direct or indirect interest you may have in any matter being
considered at a Board or committee meeting and, except as permitted under the Articles, you will not vote on any resolution of
the Board, or of one of its committees, on any matter where you have any direct or indirect interest;

 

		3.5.12	immediately report your own wrongdoing or the wrongdoing or proposed wrongdoing of any employee
or other director of the Company of which you become aware to the chairman;

 

		3.5.13	exercise your powers as a director in accordance with the Company’s policies and procedures;
and

 

		3.5.14	not do anything that would cause you to be disqualified from acting as a director.

 

		3.6	Unless the Board specifically authorises you to do so, you shall not enter into any legal or other
commitment or contract on behalf of the Company.

 

		3.7	You shall be entitled to request all relevant information about the Company’s affairs as
is reasonably necessary to enable you to discharge your duties.

 

		4	Fees and Expenses

 

		4.1	You shall be paid an annual gross fee of £50,000 (current at the date of this letter), which
shall be paid in equal instalments monthly in arrears after deduction of any taxes and other amounts that are required by law.
This annual fee shall be subject to an annual review by the Board. This fee covers all duties, including service on any Board committee.

 

		4.2	The Company shall reimburse you for all reasonable and properly documented expenses that you incur
in performing the duties of your office.

 

    4 

     

    

 

		4.3	On termination of your appointment, you shall only be entitled to such fees as may have accrued
to the date of termination, together with reimbursement in the normal way of any expenses properly incurred before that date.

 

		5	Independent Professional Advice

 

In some circumstances you may
consider that you need professional advice in the furtherance of your duties and it may be appropriate for you to seek advice from
independent advisers at the Company’s expense. A copy of the Board’s agreed procedure under which directors may obtain
such independent advice is available from the Board. The Company shall reimburse the reasonable cost of expenditure incurred by
you in accordance with its policy.

 

		6	Outside Interests

 

		6.1	You have already disclosed to the Board the significant commitments you have outside your role
in the Company, including with respect to your role as Senor Vice President, Global Head of Regulatory Affairs, Medical Documentation
and R&D Quality at H. Lundbeck A/S and Non-Executive Director at iQure Pharma Inc. You must inform the chairman in advance
of any changes to these commitments.

 

		6.2	It is accepted and acknowledged that you have business interests other than those of the Company
and have declared any conflicts that are apparent to you at present. If you become aware of any further potential or actual conflicts
of interest, these should be disclosed to the chairman and company secretary as soon as you become aware of them.

 

		6.3	The Board has determined that you are independent according to the provisions of the QCA Corporate
Governance Code.

 

		7	Confidentiality

 

		7.1	You acknowledge that all information that should be reasonably understood by you to be confidential
or proprietary information of the Company, and that is furnished or disclosed to you by the Company in the provision of your services
to the Company, is confidential to the Company and should not be released, communicated or disclosed to third parties or used for
any reason other than in the interests of the Company, either during your appointment or following termination (by whatever means),
without prior clearance from the chairman. This restriction shall (a) not apply to any disclosure required by law or by the requirements
or regulations of any applicable regulatory authority, (b) cease to apply to any confidential information which may (other than
by reason of your breach) become available to the public generally and (c) otherwise cease to apply to you on the date that is
five (5) years following the termination of your service as a director of the Company. Notwithstanding the foregoing, it is understood
that this letter shall not prohibit or otherwise restrict you from using or disclosing information that was either known to you
prior to your appointment or that was independently learned by you outside of your relationship as a director of the Company.

 

		7.2	Nothing in this paragraph 7 shall prevent you from disclosing information which you are entitled
to disclose under the Public Interest Disclosure Act 1998, provided that the disclosure is made in accordance with the provisions
of that Act.

 

    5 

     

    

 

		8	Inside Information and Dealing in the Company’s Shares

 

		8.1	Your attention is drawn to the requirements under both law and regulation as to the disclosure
of inside information, in particular to AIM Rule 11, the EU Market Abuse Regulation (Regulation 596/2014), the Disclosure Guidance
and Transparency Rules of the Financial Conduct Authority and section 52 of the Criminal Justice Act 1993 on insider dealing. You
should avoid making any statements that might risk a breach of these requirements. If in doubt, please contact the chairman or
company secretary.

 

		8.2	During your period of appointment you are required to comply with the provisions of such code as
the Company may adopt from time to time which sets out the terms for dealings by directors in the Company’s publicly traded
or quoted securities. A copy of the current share dealing code adopted by the Company will be provided to you separately.

 

		9	Training

 

On an ongoing basis, and further
to the annual evaluation process, the Company will arrange for you to develop and refresh your skills and knowledge in areas which
are mutually identified as being likely to be required, or of benefit to you, in carrying out your duties effectively. You should
try to make yourself available for any relevant training sessions which may be organised for the Board.

 

		10	Review Process

 

The performance of individual
directors and the whole Board and its committees is evaluated annually. If, in the interim, there are any matters which cause you
concern about your role you should discuss them with the chairman as soon as you can.

 

		11	Insurance and Indemnity

 

		11.1	The Company has directors’ and officers’ liability insurance with an indemnity limit
of £5,000,000 and it intends to maintain such cover for the full term of your appointment and for a period of not less than
6 years after it terminates. A copy of the policy document is available from the Board.

 

		11.2	The Company shall grant you a deed of indemnity against certain liabilities that may be incurred
as a result of your office to the extent permitted by section 234 of the Companies Act 2006.

 

		12	Changes to Personal Details

 

You shall advise the company
secretary promptly of any change in your address or other personal contact details.

 

		13	Return of Property

 

On termination of your appointment
with the Company however arising, or at any time at the Board’s request, you shall immediately return to the Company all
documents, records, papers or other property belonging to the Company or any company in the Company’s group which may be
in your possession or under your control, and which relate in any way to the Company’s or a group company’s business
affairs and you shall not retain any copies thereof.

 

    6 

     

    

 

		14	Moral Rights

 

You hereby irrevocably waive
any moral rights in all works prepared by you, in the provision of your services to the Company, to which you are now or may at
any future time be entitled under Chapter IV of the Copyright Designs and Patents Act 1988 or any similar provisions of law in
any jurisdiction, including (but without limitation) the right to be identified, the right of integrity and the right against false
attribution, and agree not to institute, support, maintain or permit any action or claim to the effect that any treatment, exploitation
or use of such works or other materials, infringes your moral rights.

 

		15	Data Protection

 

		15.1	By signing this letter you consent to the Company holding and processing data about you for legal,
personnel, administrative and management purposes including, as appropriate:

 

		15.1.1	information about your physical or mental health or condition in order to monitor sick leave and
take decisions as to your fitness to perform your duties; or

 

		15.1.2	your racial or ethnic origin or religious or similar beliefs in order to monitor compliance with
equal opportunities legislation; or

 

		15.1.3	information relating to any criminal proceedings in which you have been involved for insurance
purposes and in order to comply with legal requirements and obligations to third parties.

 

		15.2	You consent to the Company making such information available to any of its group companies, those
who provide products or services to the Company or any company in the Company’s group (such as advisers and payroll administrators),
regulatory authorities, potential or future employers, governmental or quasi-governmental organisations and potential purchasers
of the Company or the business in which you work.

 

		15.3	You also consent to the transfer of such information to the Company’s or any group company’s
business contacts outside the European Economic Area in order to further their business interests even where the country or territory
in question does not maintain adequate data protection standards.

 

		16	Third Party Rights

 

No one other than you and the
Company shall have any rights to enforce the terms of this letter.

 

		17	Entire Agreement

 

		17.1	This letter and any document referred to in it constitutes the entire terms and conditions of your
appointment and supersedes and extinguishes all previous agreements, promises, assurances, warranties, representations and understandings
between you and the Company, whether written or oral, relating to its subject matter.

 

		17.2	You agree that you shall have no remedies in respect of any representation, assurance or warranty
(whether made innocently or negligently) that is not set out in this letter and you shall not have any claim for innocent or negligent
misrepresentation based on any statement in this letter.

 

    7 

     

    

 

		18	Variation

 

No variation of this letter shall
be effective unless it is in writing and signed by you and the Company (or respective authorised representatives).

 

		19	Governing Law and Jurisdiction

 

Your appointment with the Company
and any dispute or claim arising out of or in connection with it or its subject matter or formation (including non-contractual
disputes or claims) shall be governed by and construed in accordance with the law of England and Wales and you and the Company
irrevocably agree that the courts of England and Wales shall have exclusive jurisdiction to settle any dispute or claim that arises
out of or in connection with this appointment or its subject matter or formation (including non-contractual disputes or claims).

 

Please indicate your acceptance of these
terms by signing and returning the attached copy of this letter.

 

Yours sincerely

 

Axel Glasmacher

Chairman

For and on behalf of 4D pharma plc

 

    8 

     

    

 

I confirm and agree to the above terms
of my appointment as a non-executive director of 4D pharma plc as set out in this letter.

 

Signed on       August 2020 by Katrin Rupalla

 

    9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00321-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00321-of-00352.parquet"}]]